ERBB2 and breast carcinoma: Fifteen to twenty percent of patients with early breast cancer (EBC) will have over-expression of Human Epidermal Growth Factor Receptor-2 (HER2/ERBB2), an aggressive breast cancer subtype with a classically poorer prognosis.